How long does it take for Rituximab to work in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia?

Rituximab is a monoclonal antibody therapy that targets a protein called CD20 on the surface of B cells. bA cell is a type of white blood cell that is an important part of our immune system and participates in the defense against foreign invaders. Rituximab is used to treat non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), a type of blood cancer that affects B cells. It is also used to treat autoimmune diseases such as rheumatoid arthritis, in which B cells mistakenly attack the body's cells, causing swelling and joint damage associated with the disease. Rituximab is given as an intravenous infusion.

Rituximab works rapidly in patients with non-Hodgkin lymphoma. A preliminary clinical trial showed that 24-72 hours after treatment with rituximab, CD20+ levels in the peripheral blood of patients BThe cells decreased rapidly, Treatment with rituximab A tumor biopsy taken 2 weeks later showed that the drug had attached to the tumor cells,B The number of cells has decreased, Further studies also confirmed that B cells were depleted within the first 3 weeks. In addition to these immediate effects of rituximab on the body, the researchers also investigated the time it took for the drug to cause signs of cancer to decrease and disappear. In a pivotal clinical trial of 166 patients with non-Hodgkin's lymphoma, 48% of patients who responded to treatment had a median response time of 50 days. In the same way, rituximab causes a rapid decrease in B cells in patients with CLL. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.